natgillin/translations-raw huggingface dataset:
said gravity line in fluid communication with the liquid cryogen in the tank and connected to the liquid fuel line at a junction; a first control valve positioned in the liquid fuel line between an outlet of the pump and the junction; 
crpnu liniju (210) u vezi putem fluida sa pumpom i linijom tekućeg goriva tako da je pumpa podešena da pokreće tekućeg gorivo kroz crpnu liniju prema motoru; kontrolni ventil (220) crpne linije postavljen duž crpne linije;
delivering the electronic certificate (4) to the transmitting user (1) from the processing unit (11). 
- < dostavu elektronske potvrde (4) korisniku pošiljatelju (1) iz jedinice za obradu (11).
represents a benzene ring, the ring being optionally substituted by 1 to 4 substituents selected from a C1-3 alkyl group, a halogen atom, a hydroxyl group or a C1-2 alkoxy group; and 
R2 predstavlja benzenski prsten, izborno supstituiran s 1 do 4 supstituenta, koje se bira između Ci. alkilne skupine, atoma halogena, hidroksilne skupine ili C, > alkoksi skupine; 1
A composition according to any of the preceding claims, further comprising penetration enhancers, sedimentation retarders, chelating agents, antioxidants, silicates, aroma substances, wetting agents, lanolin derivates, light stabilizers and/or antibacterial substances. 
Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time, da navedeni pripravak sadrži pojačivače penetracije, usporivače sedimentacije, kelirajuće agense, antioksidanse, silikate, arome, ovlaživače, derivate lanolina, svjetlosne stabilizatore i/ili antibakterijske supstance.
3 and 4 it is clear that the electrical motor 12 can be dimensioned relatively small as its torque is transmitted by mechanical transmission means (lever arrangement 19) into a closure force which is increasing with the course of the closure transfer movement. 
Iz gornjeg objašnjenja 1 iz slika 3 i 4 je jasno da elektromotor 12 može biti dimenzioniran tako da je relativno malen, budući da se njegov okretni moment prenosi pomoću sredstva za mehanički prijenos (naprava s polugama 19) u zatvoren sustav sila koji se povećava tijekom kretanja pri premještanju položaja.
represents a hydrogen atom, a fluoro atom or a bromo atom; 
predstavlja vodikov atom, fluorov atom ili bromov atom;
An intelligent schoolbag according to Claim 9, wherein, the control device comprises a memory chip, an MUC chip and a GPS positioning tracker, the memory chip and the GPS positioning tracker are connected to the MUC chip, the memory chip is a CF card or TF card, the MUC chip comprises a wireless transmission module and a data processing module, and the wireless transmission module is connected to the data processing module. 
Inteligentna školska torba prema zahtjevu 8, naznačena time što, kontrolni uređaj sadrži memorijski čip, MUC čip i GPS uređaj za praćenje položaja, te su memorijski čip i GPS uređaj za praćenje položaja spojeni na MUC čip, a memorijski čip je CF kartica ili TF kartica, te MUC čip sadrži modul za bežični prijenos i modul za obradu podataka, a modul za bežični prijenos je spojen na modul za obradu podataka.
wherein the clear barrier layer is in use, disposed atop the under layer and in contact with the aqueous liquid, whereby the clear barrier layer protects the structure and appearance of the under layer. 
pri čemu je prozirni nepropusni sloj u upotrebi, postavljen na sloju podloge i u dodiru je s vodenom tekućinom, pri čemu prozirni nepropusni sloj štiti strukturu i izgled sloja podloge.
wherein either the follicle stimulating hormone is urinary human follicle stimulating hormone, or the luteinising hormone is urinary human luteinising hormone, or both the follicle stimulating hormone is urinary human follicle stimulating hormone and the luteinising hormone is urinary human luteinising hormone, 
Farmaceutski pripravak ili pripravak prema zahtjevu 18 naznačen time da hormon za stimulaciju folikula (FSH) je urinarni humani hormon za stimulaciju folikula i/ili luteinizirajući hormon (LH) je urinarni humani luteinizirajući hormon (LH).
further optionally, wherein the enucleated nuclear transfer unit cell is an oocyte or an embryonic stem cell. The method of claim 4, further comprising: 
Postupak sukladno patentnom zahtjevu 4 ili 5, naznačena time, da je enukicizirana stanična jedinica nuklearnog prijenosa oocit ili embrionalna matična stanica.
Treatment can be a single dose schedule or a multiple dose schedule. 
Liječenje može biti po planu s jednom dozom ili planu s više doza.
Composition according to claim 1 wherein heparan sulfate is present at a concentration comprised between 0.1 % by weight and 1 % by weight. 
3. < Dermatološki pripravak u skladu s patentnim zahtjevom 1, naznačen time, da je heparan sulfat prisutan u koncentraciji koja se kreće između 0,5% 1 1% ukupne mase.
an LDPC decoder configured to LDPC-decode the L1 signaling data and the depunctured LDPC parity bits; and a BCH decoder configured to BCH-decode the LDPC-decoded L1 signaling data and LDPC parity bits. 
LDPC dekoder konfiguriran za LDPC-dekodiranje signalnih podataka L1 i zatvorenih LDPC paritetnih bitova; 1 BCH dekoder konfiguriran za BCH dekodiranje LDPC-dekodiranih signalnih podataka LI i LDPC paritetnih bitova.
Date of prior treatment: 12/09 
P20151444T Datum podnošenja zahtjeva u HR:
reducing a compound of formula II or an acid addition salt thereof as obtained in step c) to obtain a compound of formula I or a pharmaceutically acceptable salt thereof, and optionally isolating the compound of formula I or a pharmaceutically acceptable salt thereof as obtained in step d). 
Ruje H ili Cy-Cg alkil; da bi se dobio spoj formule II ili njegova kiselinska adicijska sol ili njegov solvat, te d) po izboru, izolacije spoja formule II ili njegove kiselinske adicijske soli ili njegovog solvata koji su dobiveni u koraku c).
In the instrument the temperature was increased from 30° C. to 300° C. at a rate of 20° C./minute, the sample was subsequently left for 5 minutes at 300° C. A slow stream of air or nitrogen was passed over the sample. 
U instrumentu temperatura je rasla od 30%C do 300"C brzinom od 20%C/minuti. Uzorak je zatim ostavljen 5 minuta pri 300"C. Polagana struja zraka ili dušika išla je preko uzorka.
A developer supply container according to Claim 3, wherein with increase of a volume of a chamber of said pump portion (2b), the pressure at least in said developer discharging chamber (3h) becomes negative. 
Spremnik za nadopunu razvijača (1) sukladno Zahtjevu 1, pri čemu s povećanjem volumena komore navedenog dijela za ubrizgavanje (2b), pritisak barem u navedenoj komori za pražnjenje razvijača (3h) postaje negativan.
Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. 
Spoj prema patentnom zahtjevu 11, naznačen time što su poremećaji i bolesti srca izabrani iz grupe koju čine poremećaji i bolesti nepravilnog srčanog rada; poremećaji i bolesti nepravilnog srčanog rada inducirani pojačanom fizičkom aktivnošću; iznenadna srčana smrt; iznenadna srčana smrt inducirana pojačanom fizičkom aktivnošću; kongestivna srčana insuficijencija; kronična opstruktivna bolest pluća; i visok krvni tlak.
The compound for use of claim 9, wherein the daily dose is about 5 mg/day. 
Spoj za uporabu sukladno patentnom zahtjevu 9, naznačeno time da je dnevna doza oko 5 mg/dan.
A pharmaceutical combination of Claim 25 wherein the hypolipidemic agent is a squalene synthetase inhibitor selected from a-phosphono-sulfonates; isoprenoid (phosphinyl-methyl) phosphonates; terpenoid pyrophosphates; farnesyl diphosphate analog A and presqualene pyrophosphate analogs; phosphinylphosphonates; and cyclopropanes. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da je hipolipidemijsko sredstvo inhibitor skvalen sintetaze odabran od a-fosfono-sulfonata, izoprenoid (fosfinil-metil) fosfonata, terpenoid pirofosfonata, farnesil difosfat analoga A i analoga preskvalen pirofostata, fosfinilfosfonata i ciklopropana.
The ship as claimed in claim 6, wherein the purification unit comprises a coarse filter arranged upstream of the effluent circuit. 
Brod prema zahtjevu 5, naznačen time da jedinica za pročišćavanje (2', 2") sadrži grubi filter (12', 12") smješten uzvodno od kruga efluenta (3', 3").
R is selected from hydrogen, halogen, hydroxy, substituted or unsubstituted alkoxy, cyano, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-8 cycloalkyl, and substituted or unsubstituted heterocyclyl; 
R je odabrano od halogen, -ORa, CN, supstituiranog ili nesupstituiranog C1-6 alkila, supstituiranog ili nesupstituiranog C2-6 alkenila, supstituiranog ili nesupstituiranog C2-6 alkinila, supstituiranog ili nesupstituiranog C3-8 cikloalkila, i supstituirane ili nesupstituirane heterocikličke skupine;
towards the centre of gravity. 
prema središtu gravitacije.
active ingredient (e.g. imazamox) 
aktivni sastojak (npr. imazamoks)
In still another embodiment of aspect 3 to be more emphasized, the present invention refers to a salt of (E)-3-[1-(4-dimethylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any acid selected from the group consisting of phosphoric acid, sulphuric acid, acetic acid, citric acid, maleic acid, fumaric acid, succinic acid, oxalic acid, stearic acid, lauric acid and methanesulphonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselnska adicijska sol (£)-3-[1-(4-dimetilaminometilbenzensulfonil)-1#-pirol-3-11]-V-hidroksiakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine fosforna kiselina, sumporna kiselina, octena kiselina, limunska kiselina, maleinska kiselina, fumarna kiselina, jantarna kiselina, oksalna kiselina, toluensulfonska kiselina i metansulfonska kiselina, ili njegov hidrat.
The exosome of claim 15, wherein the HLA antigen is HLA-A2. 
Egzosom u skladu s patentnim zahtjevom 14, naznačen time što je HLA antigen HLA-A2.
the mature type I elastase protein comprises an amino acid sequence having no more than 15, 12, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 conservative amino acid substitutions and/or no more than 5, 4, 3, 2 or 1 non-conservative amino acid substitutions as compared to the amino acid sequence of SEQ ID NO:39. 
(11) zreli tip I protein elastaze sadrži sekvencu aminokiseline koja ima ne više od 15, 12, 10, 9, 8, 7,6, 5,4,3,21li 1 supstitucije konzervativne aminokiseline u usporedbi sa sekvencom aminokiseline SEK ID BR: 39. Farmaceutski sastav prema patentnom zahtjevu 17, gdje je:
The glove according to claim 13, wherein said vaginal infection is selected from the group consisting of bacterial vaginosis, aerobic vaginitis, fungal infection and viral infection. 
Rukavica u skladu s patentnim zahtjevom 13, naznačena time što se navedena vaginalnu infekcija bira iz skupine koju čine bakterijska vaginoza, aerobni vaginitis, gljivična infekcija 1 virusna infekcija.
A pharmaceutical composition, characterized in comprising the compound or the pharmaceutically acceptable salt thereof according to any one of claims 1-4 and one or more therapeutically active substances selected from TNF-a inhibitors, COX-1/COX-2 inhibitors, COX-2 inhibitors, glucocorticoids, inactivated antibodies for interleukin, regulators for chemotactic factor receptors, antagonists for histamine HI receptors/antihistamines, leukotriene antagonists, LTD4 antagonists, VLA-4 antagonists, corticosteroids, corticosteroids analogues, B2-agonists, theophylline, leukotriene biosynthetic inhibitors, phosphodiesterase type IV inhibitors, opioids analgesics, anticoagulants, B-blocking agents, B-adrenergic agonists, angiotensin converting enzyme inhibitors or HMG-CoA reductase inhibitors. 
Farmaceutski pripravak, naznačen time što sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1-4 i jednu ili više terapeutski aktivnih tvari odabranih iz skupa koji čine inhibitori TNF-a, inhibitori COX-1/COX-2, inhibitori COX-2, glukokortikoidi, inaktivirana protutijela za interleukin, regulatori za receptore kemotaktičkog faktora, antagonisti histaminskih HI receptora/antihistaminika, antagonisti leukotriena, antagonisti LTD4, antagonisti VLA-4, kortikosteroidi, analozi kortikosteroida, B2-agonisti, teofilin, biosintetski inhibitori leukotriena, inhibitori fosfodiesteraze tipa IV, opioidni analgetici, antikoagulanti, B fB-blokatori, B-adrenergički agonisti, inhibitori angiotenzin konvertirajućeg enzima ili inhibitori HMG-CoA reduktaze.
receiving data, in particular a velocity and/or a location of a vehicle (4); 
prijem podataka, naročito brzine i lokacije vozila (4);
Conveyor means according to claim 1, wherein the drum at least adjacent to the recess is provided with a recess limiting means (229) being adapted to prevent any axial movement of the object/ item deposited in the recess beyond the lengthwise extension of the drum. 
Prema gore orijentirano skladište prema patentnom zahtjevu 14, naznačeno time, što sredstvo za ograničavanje udubljenja formiraju završni zidovi (229) bubnja.
temporal envelope adjusting means for adjusting the temporal envelope information obtained by the low frequency temporal envelope analysis means to generate adjusted temporal envelope information, the temporal envelope adjusting means using the parameter in said adjusting the temporal envelope information; temporal envelope shaping means for shaping a temporal envelope of the output signal generated by the primary high frequency adjusting means, using the adjusted temporal envelope information, to generate an output signal; and 
oblikovač vremenske ovojnice za oblikovanje vremenske ovojnice izlaznog signala koju generira primarni visokofrekventni podešavač, uz upotrebu podešenih informacija o vremenskoj ovojnici, kako bi se generiralo izlazni signal; i sekundarni visokofrekventni podešavač za obradu izlaznog signala kojeg generira generator vremenske ovojnice, gdje drugi dio postupka uključuje podešavanje pojačanja, dodavanje buke, te dodavanje sinusoida.
and/or, in the preparation of compound 5, the reaction temperature for condensation is in the range of 10-25° C.; 
i / ili u pripremi spoja 5, reakcijska temperatura za kondenzaciju je u rasponu 10-25°C;
an immunogenic fragment of an Herpes Simplex virus type 2 (HSV-2) UL19 polypeptide wherein the immunogenic fragment of UL19 comprises the amino acid sequence set forth in SEQ ID NO:12, 
Smjesa iz patentnog zahtjeva 1, naznačena time, što imunogeni fragment UL19 ima aminokiselinsku sekvencu navedenu u SEQ ID NO:12.
the CH3 1 and CH3 2 domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the CH3 1 domain is positionable in the cavity or protuberance, respectively, in the CH3 2 domain; or 
svaka od domena CH31 i CH32 sadrži ispupčenje ili šupljinu, s time da se ispupčenje ili šupljina u domeni CH31 može pozicionirati u šupljinu odnosno u ispupčenje od domene CH32; ili
Protein concentration Percent of homogeneity of the vaccine composition 
Datum objave europske prijave patenta:
The safety helmet or headpiece of claim 1, wherein the light source is configured to provide an intermittent emission of light in the interest of conserving power and extending battery life. 
Sigurnosna kaciga ili naglavni dio (10, 24, 42, 50) prema zahtjevu 1, naznačena time da je izvor svjetlosti (14, 20, 40, 52) konfiguriran da osigurava isprekidano emitiranje svjetlosti radi očuvanja energije i produljenja vijeka trajanja baterije.
A compound having Formula (5): or a pharmaceutically acceptable salt thereof, wherein: 
Spoj, naznačen time, da ima formulu (5): ma SS
9% (worsened) improvement) 15% (2 grade 
9% (pogoršanje) 15% (poboljšanje 2. stupnja)
1). A method for forming a three-dimensional image inside a transparent stone (1) according to the above is characterized in that the filling layer (2) is a transparent material which can be processed to create depth. 
Postupak kreiranja trodimenzionalne slike unutar transparentnog kamena (1) prema bilo kojem od predhodnih zahtjeva, naznačen time da navedeni drugi postupak dizajniranja je najmanje graviranje (3) formirano na unutarnjoj površini navedenog sloja punjenja rezbarenjem.
These bottles are emptied by collapse of the bottle wall by application of mechanical, pneumatic or hydraulic pressure causing the content to be squeezed out. 
Te se boce isprazne sklapanjem stijenke boce djelovanjem mehaničkog, pneumatskog ili hidrauličkog pritiska, čime se uzrokuje istiskivanje sadržaja.
10mg/kg IL-2 microaggregates can kill about ½ a test population. 
10mg/kg mikroagregata IL-2 može ubiti oko /% testne populacije.
The solution is then diluted with ethanol and added drop-wise to a 1.5 M NH3 solution. 
Otopina je razrijeđena etanolom 1 dokapana je 1.5 M otopina NHi.
The typical parenteral compositions are solutions or suspensions which contain the Zn-HA complex and a sterile aqueous carrier or an oil acceptable for parenteral use, such as polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. 
Tipični parenteralni sastavi su otopine ili suspenzije koje sadrže Zn-HA kompleks i sterilni vodeni nosač ili ulje prihvatljivo za parenteralnu upotrebu, poput polietilen glikola, polivinil pirolidona, lecitina, aracis ulja ili sezamovog ulja.
These compounds are useful as intermediates in the preparation of the compounds of the first aspect of this invention. 
Ovi spojevi su korisni kao intermdijeri u pripravljanju spojeva iz prvog aspekta izuma,
C1-6alkyl, which is unsubstituted or substituted with halogen, hydroxyl, phenyl or napthyl, 
(4) Crealkil, koji je nesupstituiran ili supstituiran sa halogen, hidroksil, fenil ili naftil,
Diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride for use according to claim 1, characterized in that it is in monohydrate crystal form. 
Dietil((6-[(1[4-(hidroksikarbamoil)feniljkarbamoil!oksi)metillnaftalen-2-il)metiamonijev klorid, - namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je u obliku kristalnog monohidrata.
In one class are compounds of formula (I), wherein M is —NHC(O)R7, wherein R7 is C1-7 alkyl, C2-7 alkenyl, C3-7 cycloalkyl, —NH—R10 or —NH—X1—R11, wherein R10 is C1-7 alkyl or C3-7 cycloalkyl, X1 is a bond or C1-7 alkyl, and R11 is a 5-6 membered heterocyclic ring optionally substituted by one or two C1-7 alkyl groups. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time, da je M -NHC(O)R;, pri čemu je R7 je Cr 7 alkil, C2; alkenil, Ca; cikloalkil, -NH-R,g ili X;-Ri 1, pri čemu je Ri9 C17 alkil ili C3.; cikloalkil, X; je veza ili CL; alkil, a R;, je petero do šesteročlani heterociklički prsten po izboru supstituiran s jednom ili dvije C,.; alkil skupine.
Item 5. The pharmaceutical preparation according to Item 4 which is used as a vasodilator, hypotensive drug, aquaretic agent, or platelet aggregation inhibitor. 
Farmaceutski pripravak prema zahtjevu 3, naznačen time, da se upotrebljava kao vazodilatorsko sredstvo, lijek za snižavanje krvnog tlaka, akvaretičko sredstvo, 1li kao inhibitor agregacije pločastih stanica.
determining, by means of a second algorithm, a corrective value of the position of each stitch cam (7) on the basis of the respective comparison result of the corresponding yarn feeder (8), if the comparison result exceeds a predetermined tolerance threshold or if it is out of a predetermined tolerance range; 
- < određivanje, pomoću drugog algoritma, korektivne vrijednosti položaja svakog ekscentra očica (7) temeljem usporedbe rezultata odgovarajućih opskrbljivača predivom (8), ukoliko rezultat usporedbe prelazi prethodno određeni prag tolerancije ili je izvan prethodno određenog opsega tolerancije;
EXAMPLES Tramadol hydrochloride was used as the active ingredient in a series of Examples. 
PRIMJERI U nizu primjera kao djelatna tvar primijenjen je tramadolhidroklorid.
Sorbitol and Methimazole; or salts thereof, and a pharmaceutically suitable excipient. 
- Sorbitol i Metimazol; ili njihovih soli, 1 farmaceutski prikladnu pomoćnu tvar.
Other proliferative disorders can also be treated according to the invention, including for example hyperplasias, fibrosis (especially pulmonary, but also other types of fibrosis, such as renal fibrosis), angiogenesis, psoriasis, atherosclerosis and smooth muscle proliferation in the blood vessels, such as stenosis or restenosis following angioplasty. 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od proliferativnog poremećaja izabranog između hiperplazija, fibroze, angiogeneze, psorijaze, ateroskleroze, stenoze ili restenoze nakon angioplastike, i drugih bolesti naznačenih proliferacijom glatkih mišića u krvnim žilama.
R2a is hydrogen, C3-8cycloalkyl, C5-7cycloalkenyl, phenyl or 5-6 membered heterocyclic group containing at least one of O, S and N, said C3-8cycloalkyl, C5-7cycloalkenyl, phenyl and 5-6 membered heterocyclic group can be optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, carboxyl, amino, C1-6alkyl and haloC1-6alkyl; 
R* je vodik, Cagcikloalkil, Cs;cikloalkenil, fenil ili 5-6 člana heterociklična skupina koja sadrži barem jedan od O, SiN, spomenuti Cagcikloalkil, Cs;cikloalkenil, fenil i 5-6 člana heterociklična skupina mogu izborno biti supstituirani s 1, 2, 3, 4, 5 ili 6 supstituenata nezavisno odabranih iz skupine koja se sastoji od halogena, cijano, hidroksila, karboksila, amino, Crsalkila i haloC; galkila;
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of claims 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
with the proviso that a carbon atom of the R1 heteroaryl is attached to the carbonyl; 
O. so: uz uvjet da ugljikov atom iz R' heteroarila je vezan na karbonil;
The method of claim 2, wherein if the biological sample is negative for JCV antibody then the subject is a candidate to receive treatment with an immunomodulator. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što nemogućnost detektiranja vezanja protutijela protiv JCV na HPVLP-e ukazuje da je subjekt kandidat da primi liječenje imunomodulatorom.
In a particular embodiment, the sugar stabiliser is trehalose. 
Vodeni farmaceutski pripravak sukladno zahtjevu 1, naznačeno time, da je stabilizator šećera trehaloza.